glp-1 drugs key developments 2025 Market Overview: Agonists and the Obesity Market | Blog Outlook for obesity in 2025:
Description
These limitations necessitate exploring alternative therapeutic options
A 2025 perspective suggested GLP-1s may influence epigenetic processes involved in age-related liver fibrosis and cancer risk [6]
GLP-1 increases insulin and decreases glucagon levels, which will result in decreased blood glucose [8, 9]
This condition is commonly seen in younger adults, and its presentation in individuals in their 40s is rare
